U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842992) titled 'A Phase II Study to Evaluate NH102 for Depression' on Feb. 16.
Brief Summary: This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.
Study Start Date: Dec. 04, 2024
Study Type: INTERVENTIONAL
Condition:
Major Depressive Disorder (MDD)
Intervention:
DRUG: NH102
5 mg twice daily over 6 weeks, followed by a 1-week tapering period.
DR...